In vivo studies using an anti-IL-19 monoclonal antibody—which binds directly to IL-19 and prevents its interaction with the IL-20R1/IL-20R2 receptor complex—have demonstrated suppression of tumor growth in esophageal squamous cell carcinoma. This evidence concerns the gene IL20RA and neoplasm.